Tiefenbacher Pharmaceuticals Successfully Prepares the Launch of Amifampridine Across Europe
At Tiefenbacher Pharmaceuticals, we are deeply committed to making high-quality, life-changing medications affordable and accessible to patients worldwide, regardless of, nationality, or income. That’s why we are excited to share that we have successfully prepared the launch of Amifampridine Tablets 10mg. This is the first generic treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), across Europe.
Amifampridine is an orphan drug and currently the only treatment available for LEMS patients. There is a critical need for 40,000 individuals worldwide aged 6 to 99 years suffering from this rare neuromuscular disorder. The product has been launched across key European markets and is marketed by our partners, ensuring broad access to patients in these regions.
A Fully In-House Supply Chain
This milestone reflects Tiefenbacher Group’s comprehensive in-house capabilities. Amifampridine was developed in our cutting-edge laboratories and manufactured in our most modern facilities in India and in Cyprus. The product has been packaged and dispatched by Tiefenbacher Group. Demonstrating our commitment to maintaining a fully internalized supply chain that underscores our dedication to quality and efficiency. This approach contributes to making the product more affordable.
Making Treatment Accessible and Affordable
LEMS is a rare condition with limited treatment options, and Amifampridine Tablets offer a much-needed, cost-effective alternative to the originator product. With a focus on better access and affordability, our product is significantly more affordable than the existing medications, ensuring that more patients can access the treatment they need without financial barriers.
Commitment to Rare Diseases
This launch marks an important step in Tiefenbacher Pharmaceuticals’ ongoing mission to address unmet medical needs. As the first generic Amifampridine on the market, our product provides new options to LEMS patients and highlights our dedication to improving patient care globally.
We are proud of our team and partners for their hard work, which made this achievement possible. This launch is a testament to the strength of our internal development and supply chain capabilities, we look forward to expanding access to Amifampridine in more markets in the near future.
In case of inquiries please reach out to licensing@tiefenbacher.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com

About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company. We are providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com